Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on the treatment of metabolic diseases, including T2D and obesity.

Long haired red satin mouse on scales
Research

Fractyl's GLP-1 gene therapy makes weight loss last in mice

Fractyl Health may have a solution for post-Ozempic and Wegovy weight gain: a gene therapy that seals GLP-1 secretion directly into pancreas cells.
Helen Floersh Jun 24, 2024 11:11am
Wall Street IPO initial public offering markets shares stock

Alto, Fractyl head to public markets with IPOs north of $100M

Feb 2, 2024 8:14am
Photo of Wall Street street sign with american flags in the background

Alto aims for $101M IPO to pave neuro development climb

Jan 30, 2024 11:37am
IPO initial public offering Wall Street

Fractyl sets out $99M IPO ambitions after busy week for biotechs

Jan 29, 2024 9:31am
Wall Street stock exchange finance shares share price Nasdaq

Hoping its GLP-1 gene therapy can beat Wegovy, Fractyl plans IPO

Dec 15, 2023 5:09am
mouse

Fractyl's GLP-1 obesity gene therapy outdoes semaglutide—in mice

Oct 4, 2023 4:24pm